PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology


Everett E. Vokes; Suresh Senan; Joseph A. Treat; Neill A. Iscoe


Clin Lung Cancer. 2009;10(3):193-198. 

In This Article

Eligibility Criteria

The major eligibility criteria include Eastern Cooperative Oncology Group performance status 0 or 1; histologic or cytologic evidence of NSCLC of other than predominantly squamous histology; unresectable stage IIIA or IIIB disease; adequate organ function, including hematologic, hepatic, renal, and pulmonary function; and weight loss ≤ 5% in the preceding 3 months. Patients would be excluded if they have ≥ 1 of the following: Pancoast tumors; significant intercurrent illness, including unstable cardiac disease; inability to discontinue nonsteroidal anti-inflammatory agents; estimated proportion of lung outside the planning target volume exposed to a radiation dose > 20 Gray (V20) exceeding 35%; and concurrent cancer from any origin that has required active therapy within the previous 5 years. All patients must provide signed informed consent.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: